We are live on ! Find out more
BRM

Boston Research & Management Portfolio holdings

AUM $421M
1-Year Est. Return 16.18%
This Fund
S&P 500
This Quarter Est. Return
+0.86%
1 Year Est. Return
+16.18%
3 Year Est. Return
+48.21%
5 Year Est. Return
+65.09%
10 Year Est. Return
+242.1%
AUM
$421M
AUM Growth
-$12.7M
Cap. Flow
-$8.14M
Cap. Flow %
-1.93%
Top 10 Hldgs %
28.54%
Holding
122
New
2
Increased
23
Reduced
48
Closed
8

Top Buys

Rank Stock Value
1
ADBE icon
Adobe
ADBE
+$953K
2
CMCSA icon
Comcast
CMCSA
+$778K
3
LLY icon
Eli Lilly
LLY
+$694K
4
UPS icon
United Parcel Service
UPS
+$340K
5
GIS icon
General Mills
GIS
+$338K

Sector Composition

Rank Sector Weight
1 Technology 12.77%
2 Healthcare 12%
3 Consumer Staples 10.95%
4 Industrials 10.3%
5 Financials 9.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SNA icon
26
Snap-on
SNA
$21.3B
$6.52M 1.55%
17,954
-170
-0.9% -$63K
IEFA icon
27
iShares Core MSCI EAFE ETF
IEFA
$186B
$6.3M 1.5%
69,552
-229
-0.3% -$21.4K
LH icon
28
Labcorp
LH
$23.2B
$6.22M 1.48%
23,308
-235
-1% -$63.6K
ABT icon
29
Abbott
ABT
$175B
$6.13M 1.46%
59,676
+2,955
+5% +$334K
DUK icon
30
Duke Energy
DUK
$97.5B
$5.99M 1.42%
45,712
+305
+0.7% +$38.1K
KO icon
31
Coca-Cola
KO
$351B
$5.63M 1.34%
74,107
-523
-0.7% -$39.5K
DHI icon
32
D.R. Horton
DHI
$42.4B
$5.53M 1.31%
40,290
-527
-1% -$79.6K
COP icon
33
ConocoPhillips
COP
$140B
$5.49M 1.3%
41,560
+382
+0.9% +$42.3K
VZ icon
34
Verizon
VZ
$182B
$5.42M 1.29%
107,993
-482
-0.4% -$22.3K
TMO icon
35
Thermo Fisher Scientific
TMO
$198B
$5.32M 1.26%
10,814
+235
+2% +$128K
PEP icon
36
PepsiCo
PEP
$187B
$5.24M 1.24%
33,749
-210
-0.6% -$32.7K
CL icon
37
Colgate-Palmolive
CL
$74.4B
$5.17M 1.23%
60,669
+595
+1% +$53K
USB icon
38
US Bancorp
USB
$98.4B
$4.94M 1.17%
95,058
SYY icon
39
Sysco
SYY
$39.1B
$4.82M 1.15%
67,635
+75
+0.1% +$6.2K
DIS icon
40
Walt Disney
DIS
$170B
$4.66M 1.11%
48,377
+1,825
+4% +$193K
IWM icon
41
iShares Russell 2000 ETF
IWM
$82.2B
$4.59M 1.09%
18,497
-1,495
-7% -$386K
XLE icon
42
State Street Energy Select Sector SPDR ETF
XLE
$38.2B
$4.58M 1.09%
74,732
-945
-1% -$50.7K
SPY icon
43
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$4.56M 1.08%
7,006
-40
-0.6% -$27.2K
LLY icon
44
Eli Lilly
LLY
$1.05T
$4.45M 1.06%
4,833
+685
+17% +$694K
MDT icon
45
Medtronic
MDT
$106B
$4.38M 1.04%
50,546
+1,508
+3% +$144K
UPS icon
46
United Parcel Service
UPS
$100B
$4.17M 0.99%
42,437
+3,172
+8% +$340K
IAU icon
47
iShares Gold Trust
IAU
$62.4B
$4.13M 0.98%
46,824
-130
-0.3% -$11.9K
EQIX icon
48
Equinix
EQIX
$101B
$4.02M 0.96%
4,106
+193
+5% +$172K
GIS icon
49
General Mills
GIS
$20.3B
$4.01M 0.95%
107,872
+7,793
+8% +$338K
VTI icon
50
Vanguard Total Stock Market ETF
VTI
$658B
$3.97M 0.94%
12,380

Similar funds

Boston Research & Management's Q1 2026 Portfolio in Review

As of Q1 2026, Boston Research & Management held 122 positions worth $421M, down 2.9% from $434M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Boston Research & Management's Q1 2026 filing shows 2 new, 23 increased, 48 reduced and 8 closed positions. Its largest new stake was Texas Instruments: 1,060 shares worth $205K. The largest sale was iShares Core S&P 500 ETF, an estimated $1.89M.

By sector, the portfolio is most concentrated in Technology at 13% of assets, down from 15% a quarter earlier, followed by Healthcare and Consumer Staples.

  • Boston Research & Management's largest Q1 2026 buy was Texas Instruments: 1,060 shares worth $205K.
  • Boston Research & Management added most to Adobe in Q1 2026, an estimated $953K increase.
  • Boston Research & Management's biggest Q1 2026 reduction was iShares Core S&P 500 ETF, cutting an estimated $1.89M.
  • Boston Research & Management fully exited iShares US Consumer Staples ETF in Q1 2026, selling an estimated $702K.
  • Boston Research & Management's ten largest holdings make up 29% of its $421M portfolio in Q1 2026.
  • Boston Research & Management opened 2 new positions and closed 8 in Q1 2026.
  • Boston Research & Management's portfolio value fell 2.9% quarter-over-quarter to $421M.

Based on Boston Research & Management's 13F filing for Q1 2026, filed 10 Apr 2026.